Drug Details

General Information of the Drug (ID: DR6727)
Name
Balsalazide
Synonyms
BALSALAZIDE; 80573-04-2; Balsalazido; Balsalazida; Balsalazidum; Balsalazidum [Latin]; Balsalazida [Spanish]; Balsalazido [Spanish]; Balsalazide Disodium; Colazide; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; UNII-P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; P80AL8J7ZP; CHEMBL1208641; CHEBI:267413; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid; C17H15N3O6; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; Giazo; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; NCGC00164634-01; Balsalazide [INN:BAN]; DSSTox_CID_20653; DSSTox_RID_79523; DSSTox_GSID_40653; 3-[[4-[(2-carboxyethylamino)-oxomethyl]phenyl]hydrazinylidene]-6-oxo-1-cyclohexa-1,4-dienecarboxylic acid; 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid; (E)-5-[[[-4-(2-Carboxyethyl)aminocarbonyl]phenyl]azo]-2-hydroxybenzoic acid; Balsalazide (INN); CAS-80573-04-2; Balsalazide-[d3]; (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; MLS001424257; BIDD:GT0772; SCHEMBL118300; SCHEMBL138311; SCHEMBL142548; CHEMBL1201346; DTXSID7040653; SCHEMBL15841310; CHEBI:94605; GTPL11569; HMS2052K19; HMS2233C19; HMS3369E09; HMS3394K19; HY-B0667; ZINC3952881; Tox21_112252; ANW-61237; MFCD00868204; s4842; ZINC13863965; AKOS015892568; Tox21_112252_1; ZINC100050064; ZINC100056740; ZINC242522365; AC-8500; CCG-101140; DB01014; KS-5215; NC00390; NE31766; VA10368; Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-; NCGC00164634-02; (3E)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; AS-17568; SMR000469221; AB0020029; FT-0602905; V0740; D07488; AB01209737-01; 573B042; A839951; Q347337; Q-200671; Q27166431; 5-[4-(2-Carboxyethylcarbamoyl)phenylazo]salicylic acid; Bacitracin zinc, Antibiotic for Culture Media Use Only; (E)-5-((4-(2-carboxyethylcarbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; 5-((4-((2-carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; 5-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl)-2-hydroxybenzoic acid; (3E)-3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 3-[[4-(3-hydroxy-3-oxopropylcarbamoyl)phenyl]hydrazinylidene]-6-oxidanylidene-cyclohexa-1,4-diene-1-carboxylic acid; 399030-81-0
    Click to Show/Hide
Molecular Type
Small molecule
Disease Indeterminate colitis [ICD-11: DD72] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C17H15N3O6
PubChem CID
54585
Canonical SMILES
C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
InChI
1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
InChIKey
IPOKCKJONYRRHP-UHFFFAOYSA-N
CAS Number
CAS 80573-04-2
ChEBI ID
CHEBI:267413
TTD Drug ID
D0A6KR
DrugBank ID
DB01014
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Parthenolide      Tanacetum parthenium     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Activity p105  Molecule Info 
Pathway MAP
Up-regulation Expression TP53  Molecule Info 
Pathway MAP
                    In-vitro Model HCT 116 CVCL_0291 Colon carcinoma Homo sapiens
SW480 CVCL_0546 Colon adenocarcinoma Homo sapiens
HT-29 CVCL_0320 Colon adenocarcinoma Homo sapiens
                    In-vivo Model Sixty specific pathogen-free mice (Balb/C female mice, 6 week) were used in this study.
                    Experimental
                    Result(s)		 Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.
Target and Pathway
Target(s) Prostaglandin G/H synthase 1 (COX-1)  Molecule Info  [3]
BioCyc C20 prostanoid biosynthesis Click to Show/Hide
KEGG Pathway Arachidonic acid metabolism Click to Show/Hide
2 Metabolic pathways
3 Platelet activation
4 Serotonergic synapse
NetPath Pathway TGF_beta_Receptor Signaling Pathway Click to Show/Hide
Panther Pathway Inflammation mediated by chemokine and cytokine signaling pathway Click to Show/Hide
Pathwhiz Pathway Arachidonic Acid Metabolism Click to Show/Hide
WikiPathways Prostaglandin Synthesis and Regulation Click to Show/Hide
2 Arachidonic acid metabolism
3 Phase 1 - Functionalization of compounds
4 Eicosanoid Synthesis
5 Selenium Micronutrient Network
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077806.
Reference 2 Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-KappaB Activation. Mol Cancer Res. 2017 Feb;15(2):141-151.
Reference 3 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link